This invention relates to medicine and concerns a pharmaceutical composition containing the peptides Ala-Asp-Glu, Lys-Asp-Glu and Asp-Glu-Gly active in relation to benign prostatic hyperplasia, its application for treatment of benign prostatic hyperplasia, and the method of treating benign prostatic hyperplasia. The composition possesses a pronounced effect that is significantly superior to that of α1-adrenergic blockers and inhibitors of 5 α-reductase. The discovered effect makes it possible to use the pharmaceutical composition containing the peptides Ala-Asp-Glu, Lys-Asp-Glu and Asp-Glu-Gly to treat benign prostatic hyperplasia.
